NCT06228326 - A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions

Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, AdultAdvanced CancerLung Cancer (NSCLC)

Interventions

BIOLOGICAL

KB707

Genetically modified herpes simplex type 1 virus

DRUG

Pembrolizumab (KEYTRUDA®)

PD-1 immune checkpoint inhibitor

DRUG

Chemotherapy

SOC chemotherapy

Trial Locations (11)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

33326

RECRUITING

BRCR Global, Weston

36303

RECRUITING

XCancer Research Network/Dothan Hematology & Oncology, Dothan

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

44718

RECRUITING

Gabrail Cancer Center Research, Canton

46202

RECRUITING

IU Simon Comprehensive Cancer Center, Indianapolis

70121

RECRUITING

Ochsner/MD Anderson Cancer Center, New Orleans

77380

RECRUITING

Renovatio Clinical, The Woodlands

79915

RECRUITING

Renovatio Clinical, El Paso

85258

RECRUITING

HonorHealth Research Institute, Scottsdale